➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Johnson and Johnson
Dow
Merck
AstraZeneca

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

ELEPSIA XR Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Elepsia Xr patents expire, and what generic alternatives are available?

Elepsia Xr is a drug marketed by Sparc and is included in one NDA. There are five patents protecting this drug.

This drug has twenty-five patent family members in eighteen countries.

The generic ingredient in ELEPSIA XR is levetiracetam. There are thirty-five drug master file entries for this compound. Seventy-six suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.

US ANDA Litigation and Generic Entry Outlook for Elepsia Xr

A generic version of ELEPSIA XR was approved as levetiracetam by MYLAN on November 4th, 2008.

  Start Trial

Summary for ELEPSIA XR
Drug patent expirations by year for ELEPSIA XR
Pharmacology for ELEPSIA XR

US Patents and Regulatory Information for ELEPSIA XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-001 Dec 20, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-002 Dec 20, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-001 Dec 20, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-002 Dec 20, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-001 Dec 20, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Sparc ELEPSIA XR levetiracetam TABLET, EXTENDED RELEASE;ORAL 204417-001 Dec 20, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ELEPSIA XR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0162036 C300028 Netherlands   Start Trial PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929
0162036 2000C/032 Belgium   Start Trial PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
Johnson and Johnson
Dow
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.